R&G PHARMASTUDIES CO., LTD. R&G PharmaStudies Co., Ltd. Share Price
Equities
301333
CNE100005K44
Healthcare Facilities & Services
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.43 CNY | +1.08% |
|
-3.27% | -40.40% |
| 06-03 | R&G PharmaStudies Co., Ltd. Approves the Election of Directors | CI |
| 06-03 | R&G PharmaStudies Co., Ltd. Approves Cash Dividend for 2023 | CI |
| Sales 2024 * | 865M 119M 9.43B | Sales 2025 * | 1.04B 143M 11.34B | Capitalization | 3.69B 508M 40.2B |
|---|---|---|---|---|---|
| Net income 2024 * | 172M 23.69M 1.87B | Net income 2025 * | 230M 31.68M 2.51B | EV / Sales 2024 * | 4.26 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3.54 x |
| P/E ratio 2024 * |
21.5
x | P/E ratio 2025 * |
16.1
x | Employees | 2,042 |
| Yield 2024 * |
6.32% | Yield 2025 * |
7.42% | Free-Float | 31.45% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.08% | ||
| 1 week | -3.27% | ||
| Current month | -13.62% | ||
| 1 month | -16.42% | ||
| 3 months | -27.84% | ||
| 6 months | -37.84% | ||
| Current year | -40.40% |
1 week
36.93
39.88
1 month
36.9347.32
Current year
36.9364.80
1 year
36.9381.38
3 years
36.9383.68
5 years
36.9383.68
10 years
36.9383.68
| Managers | Title | Age | Since |
|---|---|---|---|
Jie Wu
CEO | Chief Executive Officer | 63 | 21/08/08 |
Shu Qi Li
FOU | Founder | 59 | 21/08/08 |
Qian Zhao
DFI | Director of Finance/CFO | 40 | 31/01/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Li Peng Lan
BRD | Director/Board Member | 61 | 30/08/23 |
Le Yan Teng
BRD | Director/Board Member | 52 | 30/09/09 |
Shu Qi Li
FOU | Founder | 59 | 21/08/08 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/06/24 | 38.43 | +1.08% | 1,016,388 |
| 20/06/24 | 38.02 | +0.29% | 1,439,468 |
| 19/06/24 | 37.91 | -1.40% | 517,940 |
| 18/06/24 | 38.45 | -1.64% | 1,030,888 |
| 17/06/24 | 39.09 | -1.61% | 592,100 |
End-of-day quote Shenzhen S.E., June 20, 2024
More quotes
R&G PharmaStudies Co Ltd is a China-based company mainly engaged in the provision of professional clinical trial outsourcing services. The Company's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The Company operates its businesses primarily in the domestic market.
Calendar
27/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
38.43
CNY
Average target price
60.5
CNY
Spread / Average Target
+57.43%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -40.40% | 508M | |
| +25.21% | 88.77B | |
| -22.28% | 77.04B | |
| +3.24% | 26.87B | |
| -9.70% | 17.3B | |
| 0.00% | 16.89B | |
| +0.78% | 15.44B | |
| +77.65% | 13.11B | |
| +70.99% | 13.15B | |
| -23.68% | 13.16B |
- Stock Market
- Equities
- 301333 Stock
